UnknownPhase 2

Efficacy of Tazarotene in Treatment of Verruca Plana

Egypt80 participantsStarted 2022-04-15

Plain-language summary

Verruca plana is a common skin infection with worldwide distribution. Approximately 10% of general population is infected with flat warts and it represents up to 18 % of the patients seeking treatment for warts. Verruca plana is not merely an infectious disease but also affects the quality of patients' life. Verruca plana causes major cosmetic and social concerns. Lesions' persistence and recurrence cause frustrations and psychological distress which motivate patients to seek different treatment strategies. Verruca plana commonly affects the school aged children which augments its effect on the psychological and social development of children with stigmatization and bullying are great risks. The available treatment strategies neither ensured complete clearance of the disease nor were free of side effects. Frequently used physical removal methods are operator dependent and commonly lead to irritation, local inflammation, scars, dyspigmentation, and disfigurement. In this study we evaluate the efficacy and the safety of tazarotene gel 0.1% in the treatment of verruca plana compared to imiquimod or 5-fluorouracil

Who can participate

Age range

4 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All participants must be willing to sign informed consent; for patients younger than 18 years old, parents or guardians will sign an informed consent * Age \> 4 years. * Both sexes. * Patients with clinically and dermoscopically diagnosed plane warts. * Subject is willing and able to follow all study instructions and to attend all study visits Exclusion Criteria: * • History of hypersensitivity to any of the drugs used. * Pregnancy and lactation. * Patients with epidermodysplasia verruciformis syndrome. * Patients with eczematous skin disorders. * Presence of any active infections e.g. herpes, tuberculosis. * History of topical anti wart treatment within 4 weeks of recruitment to the study, and a 12-week period for systemic anti-wart treatment, or immunotherapy, or HPV vaccine in the last 24 weeks.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The proportion of patients with complete clearance of flat warts (Physician Wart Assessment scale PWA = 0) at the end in the four arms of the clinical trial.

Timeframe: Till complete clearance of all lesions or a maximum of 12 weeks, whichever came first

The incidence of adverse events measured by the percentage of participants developing them in the four arms of the study

Timeframe: Till complete clearance of all lesions or a maximum of 12 weeks, whichever came first

Trial details

NCT IDNCT05314127

SponsorZagazig University

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2022-10

Contact for this trial

Hagar Nofal, Dr.

01006387707 hagarnofal@aucegypt.edu

View on ClinicalTrials.gov More Warts Flat trials

Plain-language summary

Who can participate

Age range

4 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

The proportion of patients with complete clearance of flat warts (Physician Wart Assessment scale PWA = 0) at the end in the four arms of the clinical trial.

Timeframe: Till complete clearance of all lesions or a maximum of 12 weeks, whichever came first

The incidence of adverse events measured by the percentage of participants developing them in the four arms of the study

Timeframe: Till complete clearance of all lesions or a maximum of 12 weeks, whichever came first